메이저카지노

JW Pharmaceutical, led by CEO Young-Sub Shin, made a significant announcement on February 19th, revealing that their innovative dyslipidemia drug, '메이저카지노,' has exceeded million in cumulative sales in just over 27 months since its launch in October 2021 until December 2023.

메이저카지노, a 2-in-1 combination medication comprising 'Pitavastatin' and 'Ezetimibe,' has emerged as the first drug in South Korea to blend these components among statin formulations.

Market analysis by pharmaceutical research firm UBIST indicates that 메이저카지노 achieved sales of .9 million in 2022 shortly after its release, swiftly ascending to blockbuster status. Last year, it recorded sales of 70.4 billion won, more than doubling the previous year's figure and reaching the notable milestone of million in cumulative sales. Particularly noteworthy is its achievement in December 2023, recording monthly sales of .2 million, securing the third position in the market for Statin/Ezetimibe combination drugs. As of January this year, cumulative sales have soared to .4 million.

The company underscores that 메이저카지노 not only effectively reduces LDL cholesterol levels by approximately 54%, but it also stands out for its safety profile amid recent concerns about statins elevating blood sugar and potentially leading to diabetes. The key component of 메이저카지노, Pitavastatin, has been proven safe from the emergence of new-onset diabetes mellitus (NODM), a common side effect of statins. The global Summary of Product Characteristics (SmPC) for Pitavastatin monotherapy, 'Livalo,' in 32 countries includes the statement 'no signs of diabetes occurrence risk,' distinguishing it as the sole statin class with such assurance.

In the 'New England Journal of Medicine' last year, a study tested Pitavastatin's effectiveness in preventing cardiovascular events in HIV-related cardiovascular patients, showing a 35% lower incidence of events in Pitavastatin users compared to controls. The study also emphasized Pitavastatin's advantage in drug interactions for HIV patients on immunosuppressants, as it doesn't overlap with other drugs' metabolic pathways, according to the company.

A spokesperson from JW Pharmaceutical emphasized, "Building on diverse clinical data affirming the efficacy and safety of 메이저카지노, the product has solidified its position as a blockbuster, maintaining a growth trajectory." They added, "Beyond lowering LDL cholesterol levels, 메이저카지노’s advantages include minimizing various side effects, and we aim to consistently increase market share based on these strengths."